Marker Therapeutics reports sustained complete response in Phase 1 lymphoma patient at 6 months

Marker Therapeutics, Inc.

DLBCL patient who failed anti-CD19 CAR T and 3 prior therapies achieved CR at 8 weeks and remains in CR at 6 months after MT-601.
MT-601 is a multiTAA-specific T cell therapy, non-genetically engineered, well-tolerated without severe CAR T side effects like neurotoxicity.
Up to 60% of lymphoma patients relapse within one year after CAR T; this patient had relapsed within 90 days yet maintained response.
Company has enrolled additional patients in APOLLO study to replicate results; City of Hope is the trial site.
Non-clinical data shows MT-601 can eradicate lymphoma cells resistant to anti-CD19 CAR T in vitro.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.